Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
about
Sunitinib: the antiangiogenic effects and beyondAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionSunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of SunitinibEfficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaEfficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysisAngiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCurrent status of targeted therapy for advanced renal cell carcinomaSubgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerPrognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinomaAnti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.Axitinib plasma pharmacokinetics and ethnic differences.Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.Kidney Cancer Working Group report.Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.
P2860
Q28066499-2FFAA26D-F9A7-43DA-8FE8-0E93C183CDC8Q28550377-72C04F17-871A-4264-8F0C-706290A8EC7DQ33392955-083ECE44-F7C1-4539-AA82-9063E203D5D9Q33405028-130081D0-00AF-440F-B3CA-06C77E976335Q33410008-C5EFD97C-841E-44EE-B7CA-EFB6D459C2D4Q33410206-44862D8A-0EA9-4B1F-875C-3D7D3EECA4AFQ33419600-84B530C9-1DB0-4B4D-82FC-5F1B04D1908FQ33434845-CEB85360-E482-430E-870A-7089F3297305Q33437427-735F1191-2ED1-43DF-B858-9DAED13C6993Q33633431-0D0FE9A2-D674-4670-B6FB-66BE27040210Q33931392-1B070F68-0C12-4595-919F-968C7E751464Q34009449-834D54A8-29BD-4151-B2BC-8798A69659CDQ34193096-E9FFD2E3-3275-4206-BEE7-3A34338B8D31Q34657590-EE1809B8-A54D-464F-9313-66F0E536DB9BQ34982554-7F993BBF-0634-4471-8A23-5328336FB2F7Q35903850-CFEE7E84-A50E-41F7-BAC1-54752C11C84BQ36467394-A71EDA18-41B6-4602-A2D4-913FA422A5A0Q36959106-DD4D583D-9F55-4E1B-8379-5C83314C6AA9Q37387563-1B07DABA-EBC2-4501-A07B-D6497D9BE73BQ37500124-52BBEBBF-E9DF-432D-94C0-3B1F0CD3DB6FQ37650644-0A7B0BE7-0499-4846-AE78-EAD6B8A61DDBQ38004605-985C57B8-2E9F-4F16-A07A-A10B552351BEQ38091137-FC03C4A4-7053-4978-854A-1E4D7A8BFF15Q38348548-4897E446-83D7-4645-8FA8-E4FFED0B66DCQ39348852-36830C1F-8DCA-48AD-AC4F-DFAEC814E562Q42876509-26BC2ED4-DAC9-4D2B-B37A-6412F5FB96D2Q45082802-B074CE20-0DD0-4BA7-BF59-E2D704143ADEQ50600192-13651323-243D-471D-BC4E-00442BD92837Q53197402-3B029608-91F3-4535-8267-D1173527A691Q55476332-51F7FCFE-31D2-4E44-951D-E592900B26AA
P2860
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatment outcomes of sunitini ...... cer center experience in Korea
@ast
Treatment outcomes of sunitini ...... cer center experience in Korea
@en
type
label
Treatment outcomes of sunitini ...... cer center experience in Korea
@ast
Treatment outcomes of sunitini ...... cer center experience in Korea
@en
prefLabel
Treatment outcomes of sunitini ...... cer center experience in Korea
@ast
Treatment outcomes of sunitini ...... cer center experience in Korea
@en
P2093
P2860
P50
P356
P1476
Treatment outcomes of sunitini ...... cer center experience in Korea
@en
P2093
Hyo Song Kim
Joong-Bae Ahn
Jung Ryun Ahn
P2860
P356
10.4143/CRT.2009.41.2.67
P577
2009-06-30T00:00:00Z